Vivos Therapeutics, Inc. has announced that its VidaSleep™ oral appliance, equipped with FDA-cleared Unilateral Bite Block technology, has received approval from the Centers for Medicare & Medicaid ...

Vivos Therapeutics, Inc. has announced the publication of positive results from a multicenter clinical trial on its Daytime-Nighttime Appliance (DNA) for treating obstructive sleep apnea (OSA) in ...

The MarketWatch News Department was not involved in the creation of this content. LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS ...

LITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive ...

Symptoms of sleep-related breathing disorders decreased from 0.28 to 0.14, while snoring decreased by 58%. Vivos believes this breakthrough regulatory clearance represents a huge opportunity to ...

Vivos Therapeutics stock leaped after the medical-technology provider garnered FDA clearance for a device to treat sleep apnea. Vivos Therapeutics (VVOS) shares on Monday leaped after the ...

LITTLETON, Colo., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for ...

Credit: Vivos Therapeutics. The FDA clearance was based on data from 73 patients with severe OSA. The Food and Drug Administration (FDA) has cleared the Vivos CARE (complete airway repositioning ...

Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea. The U.S.

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS) , a leading medical device and technology company specializing in the ...